24 results about "Viral diarrhea" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of UH15-38 in preparation of a medicine for preventing and treating PEDV-PoRVA co-infection. According to the invention, a PEDV and PoRVA co-infected piglet model is systematically established for the first time, a high-throughput transcriptomics means is combined, an enhancement mechanism of co-infection on host pathogenicity is deeply analyzed from an immune regulation level, and based on the mechanism, UH15-38 is found to be capable of effectively treating PEDV and PoRVA co-infected piglets. Experimental data show that the UH15-38 remarkably relieves clinical diarrhea symptoms caused by co-infection, reduces the copy number of PoRVA and PEDV viruses, effectively inhibits duplication of the viruses in intestinal tracts, remarkably reduces the expression levels of IL-1beta and p-MLKL in jejunum tissues, and reduces necrotic apoptosis and inflammatory response. The UH15-38 can provide a new application value for the treatment of the porcine viral diarrhea.

The invention provides an infectious bovine rhinotracheitis virus gD protein hybridoma cell strain, a monoclonal antibody and application of the monoclonal antibody in antigen detection, and belongs to the technical field of immunodetection. The invention provides an infectious bovine rhinotracheitis virus gD protein hybridoma cell strain IBRVMab-gD-8, and the preservation number of the infectious bovine rhinotracheitis virus gD protein hybridoma cell strain IBRVMab-gD-8 is CCTCC (China Center For Type Culture Collection) NO: The monoclonal antibody generated by the infectious bovine rhinotracheitis virus gD protein hybridoma cell IBRV Mab-gD-8 strain can specifically recognize strains of all genotypes of IBRV, does not generate cross reaction with viruses such as bovine viral diarrhea / mucosal disease virus (BVDV) and the like, and has good specificity; the kit not only can be used for exogenous virus detection (cell examination method) of IBRV in bovine virus live vaccines, but also can be used for clinical detection and epidemiological investigation of IBRV.

The invention relates to a fermented traditional Chinese medicine composition for preventing and treating piglet viral diarrhea as well as a preparation method and application thereof, and relates to the technical field of livestock breeding. The feed is prepared by taking traditional Chinese medicine components as basic raw materials and adding probiotics for fermentation, and the traditional Chinese medicine components comprise the following raw materials in parts by weight: 0.5-1.5 parts of cardamine violifolia dry powder, 5-15 parts of Chinese pulsatilla root, 10-20 parts of coptis chinensis, 10-20 parts of golden cypress, 10-20 parts of ash bark, 4-8 parts of turmeric, 6-10 parts of pumpkin seeds and 4-8 parts of a ginkgo leaf extract feed additive. Through cooperation of multiple components, the immunity and antioxidant functions of the body are enhanced, the structural integrity of the intestinal tract is maintained, piglet diarrhea caused by PEDV infection is effectively relieved, and growth and development of the piglet are promoted; local specialty crops are selected as medicines, and theoretical basis and practical reference are provided for deep processing of local genuine medicinal materials and PED prevention and control.

The invention belongs to the technical field of animal pathogen molecular biology, and particularly relates to a dual quantitative fluorescent primer probe composition, a kit and an identification method for identifying hog cholera virus. Aiming at the current popular strains covering 3 genotypes, 11 gene subtypes and the like of the hog cholera gene, the invention selects 5UTR and NS3 gene sequences of hog cholera virus to design and synthesize specific primers and probes aiming at the two fragments; the specific primer has no non-specific amplification on African swine fever virus, pseudorabies virus, porcine reproductive and respiratory syndrome virus, porcine circovirus type II, porcine epidemic diarrhea and bovine viral diarrhea. The invention establishes a method for identifying the classical swine fever virus wild strain and the vaccine strain and develops a kit convenient for diagnosis, and the kit and the identification method can simultaneously identify the classical swine fever virus wild strain and the vaccine strain, have the characteristics of high sensitivity, strong specificity, good repeatability and good stability, and have extremely strong application prospects.

The application is based on machine learning model, and the polypeptide WFKDWY (166953) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 166953 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 166953 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 166953 can significantly inhibit the infection of PEDV.

The invention is suitable for the technical field of gene engineering, and provides 3Ag + mi3 protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the 3Ag + mi3 protein nanoparticles, the 3Ag + mi3 protein nanoparticles comprise E2-1b-st protein, E2-1d-st protein, gD-st protein and mi3-sc protein; the E2-1b-st protein, the E2-1d-st protein and the gD-st protein are coupled to the surface of the same mi3-sc protein through an isopeptide bond to form 3Ag + mi3 protein nanoparticles; the amino acid sequences of the E2-1b-st protein, the E2-1d-st protein, the gD-st protein and the mi3-sc protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8 in a sequence table. After animals are immunized by the 3Ag + mi3 protein nanoparticles, an effective immune protection effect can be generated, and the 3Ag + mi3 protein nanoparticles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

The invention belongs to the field of antiviral compounds, and discloses an application of a benzoylaniline compound in preparation of broad-spectrum antiviral drugs. The benzoylaniline compound has a general formula as shown in a formula I, wherein R1, R2, R3, R4 and R5 are at least one of H, C1-4 alkyl, C1-4 alkoxy, halogen, hydroxyl and nitryl; wherein H on the C1-4 alkyl group and H on the C1-4 alkoxy group are optionally substituted by halogen atoms, and the condition is that at least two of R1, R2, R3, R4 and R5 are halogens, but not more than 4; at least one of R1, R2, R3, R4 and R5 is F, but not more than 2. The compound disclosed by the invention has a relatively good in-vitro antiviral effect, and the compound BAB162 is wide in antiviral spectrum and has a remarkable inhibition effect on various viruses at low concentration. The BAB162 shows an obvious treatment effect in a piglet viral diarrhea infection model and a mouse acute hepatitis virus infection model.

The invention discloses a porcine epidemic diarrhea virus PEDV S mutant protein, a porcine rotavirus PoRV VP4 optimized protein and a preparation method of a bivalent subunit vaccine of the porcine epidemic diarrhea virus PEDV S mutant protein and the porcine rotavirus PoRV VP4 optimized protein. Aiming at PEDV S protein, 17th phenylalanine of a signal peptide is mutated into alanine, 1097th phenylalanine of HR1 and 1263rd threonine of HR2 in a heptapeptide repeat region are respectively mutated into cysteine to form a disulfide bond, the protein expression quantity and the trimer proportion are obviously improved, the expression quantity in CHO cells reaches 1530mu g / mL, and the trimer proportion reaches 85%. For PoRV VP4 protein, a flexible peptide GSSG is inserted in front of a C-terminal 6 * His tag, the problem that a nickel column cannot be combined due to C-terminal negative charge interference is solved, and efficient purification is achieved. The bivalent vaccine is prepared by equivalently mixing the two proteins and adding an M108L adjuvant, animal experiments show that the bivalent vaccine can induce piglets to generate high-titer neutralizing antibodies, the protection rates for PEDV and PoRV challenge both reach 100%, and the bivalent vaccine is good in safety. The invention provides an efficient and safe novel vaccine for prevention and control of porcine viral diarrhea, and the application value is remarkable.

This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening, a peptide sequence of FWKEAK (110616) with potential affinity for the target protein was identified. The 110616 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 110616 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 110616 sequence significantly inhibited PEDV infection.

The application discloses a porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus triple mRNA vaccine and a preparation method thereof, the triple mRNA vaccine is prepared by mixing mRNA for expressing S, M and N proteins of porcine epidemic diarrhea virus, mRNA for expressing S, M and N proteins of porcine delta coronavirus and mRNA for expressing VP4 and VP7 proteins of porcine rotavirus with liposomes, and is applied to simultaneous prevention and immunization of porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus. After sows are immunized by the triple mRNA vaccine, the sows can effectively activate the sows to generate specific antibodies and neutralizing antibodies, and piglets obtain passive immunoprotection by sucking the milk of the sows. Piglet challenge protection tests show that the protection rates of the triple mRNA vaccine on the three viruses are all 100% (5 / 5). The application simplifies the inoculation procedure, reduces the epidemic prevention cost, can achieve the effect of preventing and treating three kinds of porcine viral diarrhea by one injection, and provides a simple, convenient and efficient new triple vaccine for domestic farms.

The invention provides a bovine rotavirus VP7 protein hybridoma cell strain, a monoclonal antibody and application of the monoclonal antibody in antigen detection, and belongs to the technical field of immunodetection. The invention provides a bovine rotavirus VP7 protein hybridoma cell BRV (bovine rotavirus) Mab-VP7-23 strain, and the preservation number of the BRV Mab-VP7-23 strain is CCTCC (China Center for Type Culture Collection) NO: C2025181. The monoclonal antibody generated by the bovine rotavirus VP7 protein hybridoma cell strain BRVMab-VP7-23 can specifically recognize strains of BRV G6, G8 and G10 genotypes, does not have cross reaction with viruses such as bovine viral diarrhea / mucosal disease virus (BVDV) and the like, has good specificity, can be used for exogenous virus detection (cell inspection method) of BRV in bovine virus live vaccines, and also can be used for detecting BRV in bovine virus live vaccines. The kit can also be used for clinical detection and epidemiological investigation of BRV.

The application discloses a traditional Chinese medicine oral liquid for preventing and treating pig viral diarrhea disease and a preparation method and application thereof. The traditional Chinese medicine oral liquid comprises the following active components: honeysuckle, radix scutellariae, capillaris, viticis trifolia, gardenia, gentiana, salvia miltiorrhiza, dried tangerine or orange peel, radix notoginseng, ligustrum lucidum and liquorice. The traditional Chinese medicine oral liquid has the effects of clearing heat and resolving toxins, drying dampness and purging fire, invigorating the spleen and stomach, nourishing yin and generating fluid, and can be effectively used for preventing and treating pig viral diarrhea disease and bacterial diarrhea disease. The traditional Chinese medicine oral liquid has the characteristics of scientific prescription compatibility, wide raw material sources, simple preparation process, safe and wide application, and is suitable for industrialized breeding, and has clear efficacy, stable quality and strong market competitiveness.

The invention relates to a compound emulsion for preventing and controlling bovine viral diarrhea. Every 100 g of the compound emulsion comprises the following components by weight: 0.1 to 6.0 g of bovine viral diarrhea antibody, 2.0 to 4.0 g of solanum nigrum polysaccharide, 0.1 to 1.0 g of donaxine, 0.1 to 5.0 g of taurine, 1.0 to 3.0 g of ephedra oil, 4.0 to 10.0 g of polyoxyethylene (40) castor oil, 10.0 to 18.0 g of linoleic acid, 14.0 to 20.0 g of ethyl oleate, 15.0 to 25.0 g of span-40, and the balance of water for injection. Primary emulsion of the reemulsion is in an oil-in-water (O / W) type, and secondary emulsion of the reemulsion is in an oil-water mutual wrapping type. The invention further discloses a preparation method, the process controllability is high, and low-cost production is facilitated. The reemulsion can play a slow-release and long-acting role after intramuscular injection, the effective concentration of the antibody can be maintained in vivo for a long time, repeated medication is not needed, the stress reaction of animals is reduced, meanwhile, viruses are neutralized more thoroughly, the overall curative effect is remarkably improved, and the treatment cycle is shortened.

The invention discloses a lactobacillus salivarius HZ3 strain and application thereof in preparation of anti-bovine viral diarrhea drugs, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus salivarius HZ3 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33208, and the lactobacillus salivarius HZ3 is preserved in China General Microbiological Culture Collection Center on December 26, 2024. The bacterial suspension, the supernatant and the thermal inactivated substance of the lactobacillus salivarius HZ3 disclosed by the invention have better application potential in prevention and treatment of bovine viral diarrhea.

The invention is suitable for the technical field of gene engineering, and provides 3Ag-mi3 protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the 3Ag-mi3 protein nanoparticles, the 3Ag-mi3 protein nanoparticles comprise E2-1b-mi3 fusion protein, E2-1d-mi3 fusion protein and gD-mi3 fusion protein; the amino acid sequences of the E2-1b-mi3 fusion protein, the E2-1d-mi3 fusion protein and the gD-mi3 fusion protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 in a sequence table. After animals are immunized by the 3Ag-mi3 protein nanoparticles, an effective immune protection effect can be generated, and the 3Ag-mi3 protein nanoparticles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

The invention is suitable for the technical field of protein vaccines, and provides Zera-3Ag protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the Zera-3Ag protein nanoparticles, and the Zera-3Ag protein nanoparticles comprise E2-1b-Zeraa fusion protein, E2-1d-Zeraa fusion protein and gD-Zeraa fusion protein; the amino acid sequences of the E2-1b-Zera fusion protein, the E2-1d-Zera fusion protein and the gD-Zera fusion protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 in a sequence table. After animals are immunized by the Zera-3Ag protein nano-particles, an effective immune protection effect can be generated, and the Zera-3Ag protein nano-particles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening, a peptide sequence KYRRQH (177080) with potential affinity for the target protein was identified. The 177080 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV Nsp5 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 177080 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that 177080 significantly inhibited PEDV infection.

The application is based on machine learning model, and the polypeptide YYRKWP (168510) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 168510 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 168510 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 168510 can significantly inhibit the infection of PEDV.

The invention discloses an attapulgite composite nano-enzyme for resisting porcine viral diarrhea as well as a preparation method and application of the attapulgite composite nano-enzyme. According to the composite material, attapulgite is used as a carrier, firstly, an effective ingredient of radix isatidis is extracted through an alcohol-water mixture and loaded on the attapulgite, and then a zinc oxide-cuprous oxide heterojunction nanostructure is constructed on the surface of the attapulgite in situ by utilizing the guiding and reducing effects of the active ingredient of the radix isatidis. The composite nano enzyme obtained by the invention integrates the direct antiviral activity of radix isatidis, the enzyme-like catalytic performance of ZnO-Cu2O heterojunction and the adsorption function of attapulgite, and can efficiently inhibit intestinal pathogens such as porcine epidemic diarrhea virus and the like through the synergistic effect of triple mechanisms of adsorption enrichment, catalytic killing and traditional Chinese medicine inhibition. The material is simple in preparation process, green, safe and free of drug residues, and has wide application prospects in preparation of drugs and feed additives for preventing and treating porcine viral diarrhea.

According to the EHPA injection preparation for treating porcine viral diarrhea, Euphorbia hupehensis phenolic acid compounds (EHPA) are separated from roots of Euphorbia hupehensis for the first time and prepared into the injection preparation, after optimization, the stability of the injection preparation is high, the quality and characters of products within the shelf life are stable, the EHPA injection preparation is safe to animals, and animal experiments show that the EHPA injection preparation has good clinical application prospects. The compound has a good control effect on diarrhea caused by PEDV and / or PDCoV infection, can effectively reduce death of infected animals, and has an excellent treatment effect.

The invention belongs to the technical field of gene detection, and relates to a primer group and a kit for multiple PCR (Polymerase Chain Reaction) detection of a bovine diarrhea virus. The SapV, BNoV and BEV triple PCR detection technology established in the invention has good specificity and repeatability, can be used for rapid detection of cattle farm diarrhea virus mixed infection, and lays a technical foundation for bovine viral diarrhea pathogen epidemiological investigation.

The invention provides a vaccine for preventing and treating bovine viral diarrhea type I and type II and application, and relates to the technical field of genetic engineering.BVDV antigen protein with good immunity is obtained by constructing a CHO stable expression cell line, and transcription and protein expression levels can be remarkably improved; meanwhile, the cell line can grow in a glutamine-free culture medium, metabolites are reduced, and the cell activity and the protein yield are improved. The introduced His tag optimizes the downstream purification process, so that the production cost is reduced; the expression quantity of the purified E2 protein is higher than 5g / L, and a stable and high-yield veterinary vaccine is provided for large-scale production.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of Shuanling antidiarrheal granules and clathrate compounds thereof in preparation of antiviral drugs. According to the invention, an enterovirus infected cell model is constructed, ribavirin is taken as a positive drug, and the in-vitro antiviral effects of the Shuangling antidiarrheal granules and the volatile oil inclusion compound of the Shuangling antidiarrheal granules are preliminarily evaluated. In particular, the virus comprises RVA and / or HastV. Researches prove that the Shuangporia and poria antidiarrheal granule dry extract powder and the volatile oil clathrate compound have remarkable antiviral activity on RVA and HastV in vitro, the inhibition effect of the Shuangporia and poria antidiarrheal granule dry extract powder on RVA is superior to that of the volatile oil clathrate compound, and the inhibition effect of the volatile oil clathrate compound on HastV is superior to that of the Shuangporia and poria antidiarrheal granule dry extract powder. The invention provides a scientific basis for the application of the Shuanling antidiarrheal granule dry extract powder and the volatile oil clathrate compound in the treatment of viral diarrhea.

The invention discloses a method for rapidly testing the inactivation of a bovine viral diarrhea / mucosal disease bivalent inactivated vaccine, and relates to the field of veterinary biological products. According to the rapid detection method disclosed by the invention, whether the virus is completely inactivated or not is monitored by detecting different cDNA (complementary deoxyribonucleic acid) gene segments of type 1 and type 2 BVDV, and the specific steps are as follows: extracting total RNA (ribonucleic acid) from the inactivated BVDV, removing DNA residues, carrying out reverse transcription, respectively carrying out PCR (polymerase chain reaction) detection aiming at the type 1 BVDV E2 gene and the type 2 BVDV non-structural protein gene, and judging whether the virus is completely inactivated or not according to an electrophoresis result. According to the method, the type 1 BVDV and the type 2 BVDV can be rapidly detected after being inactivated, whether the BVDV is completely inactivated or not can be determined within 2 hours, the operation procedure of inactivation detection in the bivalent vaccine preparation process is simplified, the detection period is shortened, the cost is saved, and the inactivation detection sensitivity and the vaccine production efficiency are improved.